In our cohort, 78.3% of ICI-DM patients presented with diabetic ketoacidosis, 81.8% of patients were treated with anti-PD-1, and all had low or undetectable C-peptide levels, which is consistent with a previous report (21). The gene discussed is PDCD1; the disease is diabetic ketoacidosis.